Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 11;16(3):591-594.
doi: 10.1007/s13340-025-00825-x. eCollection 2025 Jul.

Rhabdomyolysis triggered by initiation of tirzepatide

Yoshiro Fushimi  1 , Tomohiko Kimura  1 , Junpei Sanada  1 , Masashi Shimoda  1 , Shuhei Nakanishi  1 , Hideaki Kaneto  1
Affiliations
Case Reports

Rhabdomyolysis triggered by initiation of tirzepatide

Yoshiro Fushimi et al. Diabetol Int. .

Abstract

We report a case of rhabdomyolysis triggered by initiation of tirzepatide, a novel dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The patient was a 68-year-old man with a medical history of type 2 diabetes mellitus (T2DM), dyslipidemia, and chronic kidney disease (CKD). After starting tirzepatide, he developed a significant elevation of creatine kinase (CK) and other muscle injury markers. These laboratory abnormalities rapidly returned to normal range after discontinuation of the drug. Based on the naranjo adverse drug reaction probability scale and the WHO-Uppsala Monitoring Centre (WHO-UMC) causality assessment system, the association between tirzepatide and rhabdomyolysis was classified as "probable." To our knowledge, no previous cases of tirzepatide-induced rhabdomyolysis for T2DM have been reported in the literature. Although this adverse effect appears to be extremely rare, it is important to monitor CK levels when initiating tirzepatide therapy. Early detection of muscle injury markers may help prevent serious complications and ensure the safe use of this novel antidiabetic agent.

Keywords: Adverse effect; Rhabdomyolysis; Tirzepatide; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestNone declared.

References

    1. Sonavane K, Shirsat P, Agrawal G, Agarwal B. Rhabdomyolysis associated with the use of tirzepatide. Eur J Case Rep Intern Med. 2025;12(5):005392. 10.12890/2025_005392. - DOI - PMC - PubMed
    1. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. - DOI - PubMed
    1. Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment [Internet]. Uppsala: WHO Collaborating Centre for International Drug Monitoring. Available from: https://www.who.int/publications/m/item/WHO-causality-assessment
    1. Billings SA, Hagopian S, Wahi MM, Husain R, Shrestha S. Rhabdomyolysis induced by tirzepatide: a case report and literature review. Cureus. 2023;15(12):e50227.
    1. European Medicines Agency. Vildagliptin; vildagliptin, metformin – rhabdomyolysis. In: PRAC recommendations on signals. Adopted at the PRAC Meeting of 10–13 June 2014. London: EMA; 2014. [8–9 p.]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/PRAC_recommendation...

Publication types

LinkOut - more resources